Cardio-oncology & other

Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry

Am Heart JPublished Retrospective registry cohort study

Main finding · In-hospital mortality, Q1 to Q5Result — go to the resultOdds ratio 4.67 95% CI 3.05–7.14

Authors' conclusion

Among patients hospitalized with COVID-19, cTn and NPs identified patients at high risk for an in-hospital adverse cardiovascular outcome, while elevations in D-dimer identified patients at risk for thrombotic complications.

Study context

Population
Patients hospitalized with COVID-19 at 122 US hospitals, American Heart Association (AHA) COVID-19 CVD registry, January 2020 to April 2021, with admission biomarker dataof 32,636 registry patients
Participants
26,424 patients
Exposure
Admission biomarker quintiles of D-dimer, C-reactive protein (CRP), ferritin, NPs and cardiac troponin (cTn)
Outcome
In-hospital death and a CV and thrombotic composite outcome
Follow-up
In-hospital
Methodological detailsmulticentre, 122 US hospitals
  • Multicentre
  • 122 US hospitals

Main finding

In-hospital mortality, Q1 to Q5

Odds ratio

4.67

95% CI 3.05–7.14

Q5vs Q1
OR 4.67 (95% CI 3.05–7.14)

As reported in the abstract

D-dimer mortality Q1 to Q5
14% to 35%
CRP mortality Q1 to Q5
11%-32%
Ferritin mortality Q1 to Q5
11% to 30%
cTn mortality Q1 to Q5
13% to 43%
NPs mortality Q1 to Q5
7% to 35%

Observational data: associations, not effects.

Further findings

Cardiovascular (CV) composite, adjusted

OR (95% CI)
cTn2.68 (2.00–3.59)
NPs7.14 (4.92–10.37)
OutcomeOR (95% CI)
Thrombotic events, D-dimer Q5, adjustedD-dimer9.02 (5.36–15.18)

Original publication

Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Am Heart J. Published 18 January 2023. doi:10.1016/j.ahj.2022.12.014

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.